Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
| Distributed by / for | Torrent Pharma Inc. |
| NDC | 13668-116-30 |
| Full product label | Losartan Potassium and Hydrochlorothiazide Tablets, USP, 50mg/12.5mg, a) 30-count (NDC: 13668-116-30), b) 90-count (NDC: 13668-116-90), c) 1000-count (NDC: 13668-116-10), per bottle, Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India |
| Recalling firm | Torrent Pharma Inc. |
| Distribution | Nationwide USA and Puerto Rico |
| Quantity | 331,764 bottles |
| Recall initiated | 2019-04-18 |
| Report date | 2019-05-08 |
| Recall completed | — |
| Recall number | D-1267-2019 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Basking Ridge NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗